Cargando…

Transarterial radioembolization for hepatocellular carcinoma: a review

Hepatocellular carcinoma (HCC) is the most common type of liver cancer and is the second cause of death due to malignancy in the world. The treatment of HCC is complex and includes potentially curative and palliative approaches. However, both curative and palliative treatments for HCC are often asso...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sacco, Rodolfo, Conte, Caterina, Tumino, Emanuele, Parisi, Giuseppe, Marceglia, Sara, Metrangolo, Salvatore, Eggenhoffner, Roberto, Bresci, Giampaolo, Cabibbo, Giuseppe, Giacomelli, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994804/ https://www.ncbi.nlm.nih.gov/pubmed/27574589 http://dx.doi.org/10.2147/JHC.S50359

Ejemplares similares

Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review
por: Sacco, Rodolfo, et al.
Publicado: (2017)

Radioembolization Followed by Transarterial Chemoembolization in Hepatocellular Carcinoma
por: Vardar, Baran U, et al.
Publicado: (2022)

Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma
por: Kallini, Joseph Ralph, et al.
Publicado: (2016)

Combining Immunotherapy with Transarterial Radioembolization
por: Balaban Genc, Zeynep Ceren, et al.
Publicado: (2023)

Efficacy and safety analysis of transarterial chemoembolization and transarterial radioembolization in advanced hepatocellular carcinoma descending hepatectomy
por: Feng, Rui, et al.
Publicado: (2023)

Transarterial Radioembolization for the Treatment of Advanced Hepatocellular Carcinoma Invading the Right Atrium
por: Girardet, Raphaël, et al.
Publicado: (2020)

Extrahepatic transarterial radioembolization to treat fibrolamellar hepatocellular carcinoma: A case report
por: Ljuboja, Damir, et al.
Publicado: (2020)

Radiometal-Labeled Chitosan Microspheres as Transarterial Radioembolization Agents against Hepatocellular Carcinoma
por: Chan, Hui-Wen, et al.
Publicado: (2022)

Bridging treatment prior to liver transplantation for hepatocellular carcinoma: radioembolization or transarterial chemoembolization?
por: Benkö, Tamás, et al.
Publicado: (2022)

Yttrium-90 transarterial radioembolization and capecitabine in hepatocellular carcinoma with portal vein involvement
por: Şener, Nur, et al.
Publicado: (2023)

Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis
por: Hur, Moon Haeng, et al.
Publicado: (2023)

Short-term changes of angiogenesis factors after transarterial radioembolization in hepatocellular carcinoma patients
por: Ballı, Hüseyin Tuğsan, et al.
Publicado: (2023)

Comparison between Y90 Radioembolization Plus Sorafenib and Y90 Radioembolization alone in the Treatment of Hepatocellular Carcinoma: A Propensity Score Analysis
por: Facciorusso, Antonio, et al.
Publicado: (2020)

Transarterial chemoembolization as an alternative to radioembolization is associated with earlier tumor recurrence than in radioembolization-eligible patients
por: Chung, Sung Won, et al.
Publicado: (2023)

Retrospective SPECT/CT dosimetry following transarterial radioembolization
por: Thompson, Briana C., et al.
Publicado: (2021)

Yttrium-90 transarterial radioembolization versus conventional transarterial chemoembolization for patients with hepatocellular carcinoma: a systematic review and meta-analysis
por: Yang, Yi, et al.
Publicado: (2018)

Choi criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for hepatocellular carcinoma
por: WENG, ZHIHONG, et al.
Publicado: (2013)

Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients
por: Teyateeti, Ajalaya, et al.
Publicado: (2020)

Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients
por: Yim, Sun Young, et al.
Publicado: (2022)

Yttrium-90 transarterial radioembolization for liver metastases from medullary thyroid cancer
por: Puleo, Luciana, et al.
Publicado: (2022)

Sarcopenia Worsening One Month after Transarterial Radioembolization Predicts Progressive Disease in Patients with Advanced Hepatocellular Carcinoma
por: Vallati, Giulio Eugenio, et al.
Publicado: (2021)

Transarterial Radioembolization (TARE) Agents beyond (90)Y-Microspheres
por: Bouvry, C., et al.
Publicado: (2018)

Transarterial radioembolization with Yttrium-90: current status and future prospects
por: Yang, Hua-Yu, et al.
Publicado: (2020)

Novel (175)Yb-Poly (L-Lactic Acid) Microspheres for Transarterial Radioembolization of Unrespectable Hepatocellular Carcinoma
por: Jamre, Mina, et al.
Publicado: (2019)

A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study
por: Lam, Marnix, et al.
Publicado: (2022)

Advanced Stage Hepatocellular Carcinoma Successfully Treated with Transarterial Radioembolization and Multi-tyrosine Kinase Inhibitor Therapy
por: Goh, Myung Ji, et al.
Publicado: (2020)

Transarterial radioembolization for liver tumors as neoadjuvant therapy: three case reports
por: Carvalho, Vithor de Oliveira, et al.
Publicado: (2020)

Diagnostic Performance of Theranostic Radionuclides Used in Transarterial Radioembolization for Liver Cancer
por: Li, Rou, et al.
Publicado: (2021)

Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments
por: Cappelli, Alberta, et al.
Publicado: (2014)

LI-RADS Version 2018 Treatment Response Algorithm: Diagnostic Performance after Transarterial Radioembolization for Hepatocellular Carcinoma
por: Yoon, Jongjin, et al.
Publicado: (2021)

Hepatic decompensation after transarterial radioembolization: A retrospective analysis of risk factors and outcome in patients with hepatocellular carcinoma
por: Reincke, Marlene, et al.
Publicado: (2022)

Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study
por: Kolligs, Frank, et al.
Publicado: (2022)

Non-Invasive Imaging Biomarkers to Predict the Hepatopulmonary Shunt Fraction Before Transarterial Radioembolization in Patients with Hepatocellular Carcinoma
por: Hamm, Charlie Alexander, et al.
Publicado: (2023)

Imaging evaluation following transarterial radioembolization with yttrium-90 microspheres downstaging hepatocellular carcinoma: the first case in China
por: Li, Xiaoming, et al.
Publicado: (2023)

Selecting the Appropriate Downstaging and Bridging Therapies for Hepatocellular Carcinoma: What Is the Role of Transarterial Radioembolization? A Pooled Analysis
por: Lopez-Lopez, Victor, et al.
Publicado: (2023)

Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis
por: Rognoni, Carla, et al.
Publicado: (2018)

Transarterial RAdioembolization versus ChemoEmbolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial
por: Seinstra, Beatrijs A, et al.
Publicado: (2012)

Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma
por: Mohamed, Mostafa, et al.
Publicado: (2015)

Inter-observer variability of (90)Y PET/CT dosimetry in hepatocellular carcinoma after glass microspheres transarterial radioembolization
por: Meyers, Nicolas, et al.
Publicado: (2020)

Effect of Yttrium-90 transarterial radioembolization in patients with non-surgical hepatocellular carcinoma: A systematic review and meta-analysis
por: Lemieux, Simon, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hhh8dg4ceinbb50nk84l30l0nd